Related Experiment Video

Updated: Mar 8, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.4K

Zinplava Tackles Toxins Of Hard-to-Treat C. Difficile

Thomas Morrow

    Managed Care (Langhorne, Pa.)
    |January 26, 2017
    PubMed

    Insights

    Merck

    Area of Science:

    • Infectious Diseases
    • Immunology
    • Pharmacology

    Background:

    • Clostridioides difficile infection (CDI) is a significant healthcare challenge.
    • Recurrent CDI poses a substantial burden on patients and healthcare systems.
    • Antibiotic therapy for CDI can increase the risk of recurrence.

    Purpose of the Study:

    • To summarize the FDA approval of bezlotoxumab (Zinplava).
    • To highlight its indication for reducing CDI recurrence.
    • To specify the patient population eligible for this treatment.

    Main Methods:

    • Bezlotoxumab is a monoclonal antibody targeting C. difficile toxin B.
    • Clinical trials evaluated its efficacy in preventing CDI recurrence.
    • The study population included adult patients at high risk for recurrence.

    Main Results:

    • Bezlotoxumab demonstrated a reduction in the recurrence of C. difficile infection.
    • The treatment is indicated for patients receiving concurrent antibiotic therapy.
    • Eligibility is restricted to individuals aged 18 years and older with high recurrence risk.

    Conclusions:

    • Bezlotoxumab (Zinplava) is approved by the FDA for preventing recurrent CDI.
    • It offers a new therapeutic option for high-risk patients.
    • This approval addresses a critical unmet need in CDI management.

    More Related Videos

    Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R2029106:51

    Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

    Published on: December 10, 2016

    13.4K
    Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians06:49

    Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

    Published on: March 14, 2014

    12.1K

    Related Concept Videos

    Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

    Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

    Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
    1.7K
    Pharmaceutical Poisoning: Treatment Strategies01:26

    Pharmaceutical Poisoning: Treatment Strategies

    Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
    103
    Prevention of Further Absorption of Poison01:14

    Prevention of Further Absorption of Poison

    In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
    1.3K
    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

    Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
    621
    Pneumonia IV: Management01:28

    Pneumonia IV: Management

    The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
    Bacterial Pneumonia Treatment
    For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
    979
    Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

    Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

    Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
    588